PARP1 and medulloblastoma: In conclusion, our study provides evidence that PARP1 inhibition with Olaparib enhances radiation sensitivity of pediatric ependymoma, medulloblastoma and pediatric HGG cells in vitro, thereby providing the basis for further in vivo studies, aiming at clinical trials combining PARP inhibitors upfront with (chemo)radiotherapy.